BioCentury
ARTICLE | Clinical News

Anthra, Medeva Pharmaceuticals Inc. regulatory update

October 5, 1998 7:00 AM UTC

The FDA granted Orphan Drug status and marketing approval for Valstar, Anthra's anthracycline derivative valrubicin to treat carcinoma in situ of the bladder in patients who are refractory to BCG the...